PURPOSE: Nodular lymphocyte predominance Hodgkin's lymphoma is a very rare disease, characterized by an indolent clinical course, with sometimes very late relapses occurring in a minority of all patients. Considerable discussion is ongoing on the treatment of primary and relapsed disease. PATIENTS AND METHODS: A group of 9 patients were irradiated to a dose of 4 Gy on involved areas only. RESULTS: After a median follow-up of 37 months (range, 6-66), the overall response rate was 89%. Six patients had complete remission (67%), two had partial remission (22%), and one had stable disease (11%). Of 8 patients, 5 developed local relapse 9-57 months after radiotherapy. No toxicity was noted. CONCLUSION: In nodular lymphocyte predominance Hodgkin's lymphoma, low-dose radiotherapy provided excellent response rates and lasting remissions without significant toxicity.
PURPOSE: Nodular lymphocyte predominance Hodgkin's lymphoma is a very rare disease, characterized by an indolent clinical course, with sometimes very late relapses occurring in a minority of all patients. Considerable discussion is ongoing on the treatment of primary and relapsed disease. PATIENTS AND METHODS: A group of 9 patients were irradiated to a dose of 4 Gy on involved areas only. RESULTS: After a median follow-up of 37 months (range, 6-66), the overall response rate was 89%. Six patients had complete remission (67%), two had partial remission (22%), and one had stable disease (11%). Of 8 patients, 5 developed local relapse 9-57 months after radiotherapy. No toxicity was noted. CONCLUSION: In nodular lymphocyte predominance Hodgkin's lymphoma, low-dose radiotherapy provided excellent response rates and lasting remissions without significant toxicity.
Authors: Chelsea C Pinnix; Sarah A Milgrom; Chan Yoon Cheah; Jillian R Gunther; Ethan B Ludmir; Christine F Wogan; Loretta J Nastoupil; Sattva S Neelapu; Jason Westin; Hun J Lee; Swaminathan P Iyer; Raphael E Steiner; Luis E Fayad; Nathan H Fowler; Michael L Wang; Felipe Samaniego; Maria A Rodriguez; Amy E Rich; L Jeffrey Medeiros; Bouthaina S Dabaja Journal: Blood Adv Date: 2019-05-14
Authors: L Strobbe; L L F G Valke; I J Diets; M van den Brand; K Aben; J M M Raemaekers; K M Hebeda; J H J M van Krieken Journal: Ann Hematol Date: 2016-01-05 Impact factor: 3.673